## CRL: Charles River Laboratories International, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.15 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($171.83)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $185 | $170 | +9% |
| 2025-11-10 | TD Cowen | $197 | $205 | -4% |
| 2025-11-06 | JP Morgan | $165 | $160 | +3% |
| 2025-11-06 | Barclays | $210 | $195 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |
| 2025-11-10 | TD Cowen | main | Buy |
| 2025-11-06 | JP Morgan | main | Neutral |
| 2025-11-06 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Volume divergence: price rising (+2.1% MRS) on declining volume (69% of avg) suggests distribution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +8%) could attract flows.
- Momentum building: MRS_20 improving +2.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.15 indicates undervaluation relative to growth. Forward P/E 16.9x stretched relative to 7% growth. Analyst sentiment positive (4 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 1.64 |
| 52W Range | $91.86 - $204.47 |
| Short Interest | 5.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.15 |
| Forward P/E | 16.9 |
| Current P/E | 18.0 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 4.1% to 6.2% (+2.1% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 at 3.0% confirms short-term momentum alignment. AM_20 at 8.1% shows strong absolute momentum above own 20MA. Outperforming sector by 6.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.54), confirming momentum. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.15% (CS: 90) | Strong |
| RSI_14 | 63.2 | Neutral |
| MACD Histogram | 1.54 | Bullish |
| vs SMA20 | 1.081x | Above |
| vs SMA50 | 1.069x | Above |
| vs SMA200 | 1.186x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $184.67
- **Stop Loss:** $171.83 (7.0% risk)
- **Target:** $210.35 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 73
- **Position Value:** $13,480.91
- **Portfolio %:** 13.48%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*